Surface Oncology, Inc. (SURF) News
Filter SURF News Items
SURF News Results
|Loading, please wait...|
SURF News Highlights
- SURF's 30 day story count now stands at 2.
- Over the past 7 days, the trend for SURF's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SURF are AFMD, DZSI and ES.
Latest SURF News From Around the Web
Below are the latest news stories about Surface Oncology Inc that investors may wish to consider to help them evaluate SURF as an investment opportunity.
The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.
There's only one day of trading left so let's start it off right with a look at the biggest pre-market stock movers for Friday.
AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.
The big shareholder groups in Surface Oncology, Inc. ( NASDAQ:SURF ) have power over the company. Institutions often...
SRF388, a First-in-Class Anti-IL-27 Antibody, Demonstrates Monotherapy Activity in Ongoing Phase 1 Study; Enrollment Continues for Phase 2 Monotherapy Expansion and Combination Cohorts SRF617, a CD39 Inhibitor, Demonstrates Good Tolerability in Ongoing Phase 1 Study; Phase 2 Dose Confirmed and Enrollment Continues for Combination Cohorts CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunot
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Surface Oncology, Inc...
Brings 25 years of strategic leadership experience across healthcareCAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the company’s board of directors. Ms. Torres has over 25 years of executive leadership experience in healthcare across the consumer, biopharmaceutical and medical device sectors.
Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy.